diff --git a/screenshot-test/__baseline_snapshots__/Precision Oncology Therapies Page without Login-snap.png b/screenshot-test/__baseline_snapshots__/Precision Oncology Therapies Page without Login-snap.png index 7d0d0d4b8..dfdb4df99 100644 Binary files a/screenshot-test/__baseline_snapshots__/Precision Oncology Therapies Page without Login-snap.png and b/screenshot-test/__baseline_snapshots__/Precision Oncology Therapies Page without Login-snap.png differ diff --git a/src/main/webapp/app/config/constants.tsx b/src/main/webapp/app/config/constants.tsx index de7470b38..37e471060 100644 --- a/src/main/webapp/app/config/constants.tsx +++ b/src/main/webapp/app/config/constants.tsx @@ -793,6 +793,7 @@ export type DataRelease = { }; export const DATA_RELEASES: DataRelease[] = [ + { date: '02082024', version: 'v4.14' }, { date: '12212023', version: 'v4.13' }, { date: '12062023', version: 'v4.12' }, { date: '11132023', version: 'v4.11' }, diff --git a/src/main/webapp/app/pages/newsPage/ChangedAnnotatonListItem.tsx b/src/main/webapp/app/pages/newsPage/ChangedAnnotatonListItem.tsx index 3f853d5f1..89df005c6 100644 --- a/src/main/webapp/app/pages/newsPage/ChangedAnnotatonListItem.tsx +++ b/src/main/webapp/app/pages/newsPage/ChangedAnnotatonListItem.tsx @@ -5,6 +5,7 @@ import { CHANGED_ANNOTATION_ADDITIONAL_DRUG_DIFF_LEVEL_COLUMNS, GENE, MUTATION, + CHANGED_ANNOTATION_DRUG_REMOVAL_COLUMNS, } from 'app/pages/newsPage/NewsPageContent'; import { SimpleTable, SimpleTableRow } from 'app/components/SimpleTable'; import { Row } from 'react-bootstrap'; @@ -24,6 +25,7 @@ export enum AnnotationColumnHeaderType { DRUG, ADDITIONAL_SAME_LEVEL_DRUG, ADDITIONAL_DIFF_LEVEL_DRUG, + DRUG_REMOVAL, } export const ChangedAnnotationListItem = (props: { @@ -55,6 +57,12 @@ export const ChangedAnnotationListItem = (props: { useOneLineRowClass = false; defaultTitle = 'Changed Annotation'; break; + case AnnotationColumnHeaderType.DRUG_REMOVAL: + annotationColumnHeader = CHANGED_ANNOTATION_DRUG_REMOVAL_COLUMNS; + useOneLineRowClass = false; + defaultTitle = + 'Updated therapeutic implications - Removal of therapie(s) and changed tumor type-specific level of evidence for an alteration(s)'; + break; case AnnotationColumnHeaderType.LEVEL: default: annotationColumnHeader = CHANGED_ANNOTATION_LEVEL_COLUMNS; diff --git a/src/main/webapp/app/pages/newsPage/NewsPage.tsx b/src/main/webapp/app/pages/newsPage/NewsPage.tsx index 221aae7f8..0907df53a 100644 --- a/src/main/webapp/app/pages/newsPage/NewsPage.tsx +++ b/src/main/webapp/app/pages/newsPage/NewsPage.tsx @@ -91,6 +91,7 @@ export default class NewsPage extends React.Component<{
+ diff --git a/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx b/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx index b963df0db..da3d67e44 100644 --- a/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx +++ b/src/main/webapp/app/pages/newsPage/NewsPageContent.tsx @@ -79,6 +79,7 @@ export const CURRENT_LEVEL_OF_EVIDENCE = 'Current Level of Evidence'; export const PREVIOUS_LEVEL_OF_EVIDENCE = 'Previous Level of Evidence'; export const DRUGS_ADDED_TO_ONCOKB = `Drug(s) added to ${ONCOKB_TM}`; export const DRUGS_CURRENTLY_IN_ONCOKB = `Drug(s) currently in ${ONCOKB_TM}`; +export const DRUGS_REMOVED_FROM_ONCOKB = `Drug(s) removed from ${ONCOKB_TM}`; export const PREVIOUS_BIOMARKER_ASSOCIATION = 'Previous Biomarker Association'; export const CURRENT_BIOMARKER_ASSOCIATION = 'Current Biomarker Association'; @@ -144,6 +145,17 @@ export const CHANGED_ANNOTATION_ADDITIONAL_DRUG_DIFF_LEVEL_COLUMNS = [ { name: EVIDENCE }, ]; +export const CHANGED_ANNOTATION_DRUG_REMOVAL_COLUMNS = [ + { name: GENE }, + { name: MUTATION }, + { name: CANCER_TYPE }, + { name: PREVIOUS_LEVEL }, + { name: CURRENT_LEVEL_OF_EVIDENCE }, + { name: DRUGS_CURRENTLY_IN_ONCOKB }, + { name: DRUGS_REMOVED_FROM_ONCOKB }, + { name: EVIDENCE }, +]; + export const CDX_COLUMNS = [ { name: LEVEL }, { name: GENE }, @@ -200,6 +212,215 @@ const EVIDENCE_COLUMN_SEPARATOR = '; '; // https://stackoverflow.com/questions/41947168/is-it-possible-to-use-keyof-operator-on-literals-instead-of-interfaces export const NEWS_BY_DATE: { [date: string]: NewsData } = { + '02082024': { + news: [ + + Updated therapeutic implications - Demotion of tumor type-specific level + of evidence for an alteration(s) + + + + + + + + + + + + + + + + + + + + + + + + +
{GENE}{MUTATION}{CANCER_TYPE}{DRUGS}{PREVIOUS_LEVEL}{CURRENT_LEVEL}{REASON}
+ + + + Fusions (excluding FGFR3-TACC3 Fusion and FGFR3-BAIAP2L1 + Fusion which remain Level 1) + + Bladder CancerErdafitinib12 + + + Adherence to FDA-drug label and CDx for Erdafitinib + + + Inclusion in NCCN Bladder Cancer Guidelines V3.2023 + + + +
+ + , + + Updated therapeutic implications - Promotion of tumor type-specific + level of evidence for an alteration(s) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
{GENE}{MUTATION}{CANCER_TYPE}{DRUGS}{PREVIOUS_LEVEL}{CURRENT_LEVEL}{REASON}
+ + + + + {['S371C', 'G380R', 'K650'].map(alt => ( + + ))} + + + Bladder CancerErdafitinib3A2 + {' '} + + + Adherence to FDA-drug label and CDx for Erdafitinib + + + Inclusion in NCCN Bladder Cancer Guidelines V3.2023 + + + +
+ + + + Oncogenic Mutations (excluding G370C, R248C, S249C, Y373C + which remain Level 1) + + 42
+ + + + + + + Dedifferentiated Liposarcoma, Well-Differentiated Liposarcoma + +
+
+ {DRUGS_CURRENTLY_IN_ONCOKB}: +
+
Milademetan (Level 4)
+

+
+ {DRUGS_ADDED_TO_ONCOKB}: +
+
Brigimadlin (Level 3A)
+
+ 		43A + +
+ + , + ], + changedAnnotations: [ + { + columnHeaderType: AnnotationColumnHeaderType.DRUG_REMOVAL, + content: [ + [ + 'FGFR2', + 'Fusions', + 'Bladder Cancer', + 'Level 1', + 'No Level', +
+
Erdafitinib (Level 1)
+
AZD4547 (Level 4)
+
, + 'Erdafitinib, AZD4547', + + + Amendment to the FDA-drug label for Erdafitinib + + + 4/25 (16%) response rate for FGFR2/3 fusion+ bladder cancer, 0/6 + (0%) response for FGFR2 fusion+ bladder cancer + + + , + ], + ], + }, + ], + updatedImplicationTitle: + 'Updated therapeutic implications - New alteration(s) with a tumor type-specific level of evidence', + updatedImplication: [ + [ + '3A', + 'MDM2', + 'Amplification', + 'Intimal Sarcoma', + 'Milademetan', + , + ], + ], + newlyAddedGenes: [ + 'ANKRD26', + 'ARHGAP26', + 'ATIC', + 'CD70', + 'ERCC1', + 'FGF1', + 'FGF2', + 'FGF5', + 'HFE', + 'HOXA11', + 'MN1', + 'PML', + 'SRP72', + 'TNFRSF17', + ], + }, '01172024': { priorityNews: [ diff --git a/src/main/webapp/app/pages/oncologyTherapiesPage/oncologyTherapiesPage.tsx b/src/main/webapp/app/pages/oncologyTherapiesPage/oncologyTherapiesPage.tsx index 93ff4b1df..bf44706a1 100644 --- a/src/main/webapp/app/pages/oncologyTherapiesPage/oncologyTherapiesPage.tsx +++ b/src/main/webapp/app/pages/oncologyTherapiesPage/oncologyTherapiesPage.tsx @@ -474,14 +474,15 @@ const OncologyTherapiesPage: React.FunctionComponent<{}> = props => { 'https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications' } > - Content current as of 12/15/2023 + Content current as of 1/19/2024
The following US Food and Drug Administration (FDA)-approved - oncology drugs are categorized by drug class and mechanism of - action. Each drug is further classified as to whether it qualifies - as a targeted therapy or precision oncology therapy based on{' '} + oncology drugs post June 1998 are categorized by drug class and + mechanism of action. Each drug is further classified as to whether + it qualifies as a targeted therapy or precision oncology therapy + based on{' '} Suehnholz et al., Cancer Discovery 2023 {' '} diff --git a/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.json b/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.json index 2db81f597..be607c64e 100644 --- a/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.json +++ b/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.json @@ -1462,7 +1462,7 @@ { "year": "2019", "tx": "Erdafitinib", - "biomarker": "FGFR2 Fusions, FGFR3 Fusions, S249C, R248C, G370C, Y373C", + "biomarker": "FGFR3-TACC3 Fusion, FGFR3-BAIAP2L1 Fusion, FGFR3 S249C, R248C, G370C, Y373C", "agentClass": "Small molecule kinase inhibitor", "drugTarget": "Multi-targeted kinase inhibitor (targets include FGFR1/2/3/4 among others)", "targetedTx": "Y", diff --git a/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.xlsx b/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.xlsx index 4bb122286..baf06cd93 100644 Binary files a/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.xlsx and b/src/main/webapp/content/files/oncologyTherapies/fda_approved_oncology_therapies.xlsx differ diff --git a/src/main/webapp/content/images/oncokb_summary.png b/src/main/webapp/content/images/oncokb_summary.png index ec76f9f97..ce480ac18 100644 Binary files a/src/main/webapp/content/images/oncokb_summary.png and b/src/main/webapp/content/images/oncokb_summary.png differ diff --git a/src/main/webapp/index.html b/src/main/webapp/index.html index ac6738704..e5d3591e1 100644 --- a/src/main/webapp/index.html +++ b/src/main/webapp/index.html @@ -15,7 +15,7 @@ - + @@ -23,7 +23,7 @@ - +